We use cookies to improve the performance of our site and optimize it for our users. Customize Cookie Preferences

Sign Up Today and Learn More About CellCentric Stock

Invest in or calculate the value of your shares in CellCentric or other pre-IPO companies through EquityZen's platform.

Get Started

CellCentric Stock

CellCentric is a biotechnology company that develops p300/CBP inhibitors to treat cancer and multiple myeloma.

About CellCentric Stock

Founded

2003

Industries

Software, Artificial Intelligence, Data and Analytics

CellCentric is a clinical-stage biotech company focusing on the inhibition of p300/CBP to treat specific cancers, particularly solid tumors. The programme also has potential clinical utility in non-small cell lung, breast, and colon cancer. The company's oral drug, Inobrodib, is currently in Phase I/II clinical trials and aims to address cancers such as multiple myeloma. The company is committed to science-driven solutions for cancer, with a patient-focused approach to novel therapies.

CellCentric Press Mentions

Stay in the know about the latest news on CellCentric

CellCentric Management

Leadership team at CellCentric

CEO

Will West

Chief Financial Officer and Chief Business Officer

Celia Economides

Locked Features

Join now and verify your accreditation status to gain access to:

  • CellCentric Current Valuation
  • CellCentric Stock Price
  • CellCentric Management
  • Available deals in CellCentric and all other companies with relevant Deal Offering documents
  • EquityZen's proprietary data and insights, which may include
    • CellCentric Cap Table and Funding History by Share Class and Liquidity Preferences
    • CellCentric Revenue and Financials
    • CellCentric Highlights
    • CellCentric Business Model
    • CellCentric Risk Factors
  • CellCentric Research Report from SACRA Research
Join Now

Trading CellCentric Stock

How to invest in CellCentric stock?

Accredited investors can buy pre-IPO stock in companies like CellCentric through EquityZen funds. These investments are made available by existing CellCentric shareholders who sell their shares on our platform. Typically, these are early employees who need to fund a life event – house, education, etc. Accredited investors are then offered the opportunity to invest in this stock through a fund, like those used by hedge funds serving large investors. While not without risk, investing in private companies can help investors reach goals of portfolio diversification, access to potential growth and high potential return. Learn more about our Guided Investment process here.

How to sell CellCentric stock?

Shareholders can sell their CellCentric stock through EquityZen's private company marketplace. EquityZen's network includes over 370K accredited investors interested in buying private company stock. Learn more about the easy and guided Shareholder process here.

If I invest, how do I exit my investment?

There are two ways to exit your private company investment on EquityZen's marketplace. The first is if the company has an exit event like an IPO, merger or acquisition. In that case, we will distribute the shares and/or cash to you directly. The second way is through an Express Deal on EquityZen, if eligible. An Express Deal allows you to sell your allocation of private shares in a given private company to another investor on EquityZen's marketplace. More information on Express Deals can be found here and exit information can be found here.

Why choose EquityZen?

Since 2013, the EquityZen marketplace has made it easy to buy and sell shares in private companies. EquityZen brings together investors and shareholders, providing liquidity to early shareholders and private market access to accredited investors. With low investment minimums through our funds and with more than 46K private placements completed across 450+ companies, EquityZen leads the way in delivering "Private Markets for the Public."

More Like CellCentric